VRTX Vertex Pharmaceuticals (VRTX) Q1 FY26 earnings call
Vertex Pharmaceuticals delivered a strong Q1 FY26, marked by 8% revenue growth driven by its CF portfolio and significant contributions from new disease areas like CASGEVY and JOURNAVX. The company achieved rapid progress in its pipeline, notably with the "sparkling" Phase III IgAN data for Pove leading to a swift BLA submission, and advancements in other renal programs and type 1 diabetes. While the VX-522 program was discontinued due to tolerability issues, Vertex remains committed to addressing the remaining unmet needs in CF and expanding its therapeutic franchises.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
VRTX operating KPIs by quarter
| KPI | Jun 2025 Q2 FY25 | Sep 2025 Q3 FY25 | Dec 2025 Q4 FY25 | Change vs prior quarter |
|---|---|---|---|---|
| Patients CASGEVY | 16And finally, a total of 29 patients have completed their treatment journey and received their infusions of CASGEVY edited cells, including 16 patients in the second quarter of 2025.Source: earnings call transcript | 10And a total of 39 patients have received their infusions of CASGEVY edited cells, including 10 patients in the third quarter of 2025.Source: earnings call transcript | 30You can see the evidence of this acceleration in our excellent quarter 4 '25 results, where CASGEVY had 111 new patient initiations, 37 patients with first cell collections and 30 patients receiving infusions, driving $54 million in quarterly revenue.Source: earnings call transcript | +200% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.